mAbLab
A Deep Learning Approach to Monoclonal Antibody Engineering using Transformer Architecture for Amino Acid Sequence Prediction of CDR-H3 Sites
300% Cheaper
Multimodal Machine Learning Model
80% Shorter Lead Times
Highly-Specific & Stronger Therapeutics
The Problem
Emergent viral and antibiotic-resistant diseases vastly outpace R&D, set to claim 100 million lives by 2050 (Salam et al 23). Monoclonal antibodies, highly specific immune proteins, provide a promising solution in curbing their spread, constituting a $300 billion market. However, development into the industry is stifled by long lead times, exorbitant costs, and high risk of pathogenicity (Hernandez et al 18).
The mAbLab Advantage
In order to address the discrepancies in status quo mAb development, mAbLab shifts the paradigm by optimizing 4 factors inhibiting substantial progress.
Images from Left to Right: Bloomberg , Alamy, Quartz, Animal Research